Secondary hyperparathyroidism in kidney disease can raise PTH before symptoms appear. Learn causes, calcium and phosphate tests, risks and treatment.

Secondary hyperparathyroidism (SHPT) is an increase in parathyroid hormone (PTH) that develops as the parathyroid glands respond to another disorder. In chronic kidney disease (CKD), changes in phosphate handling, active vitamin D and calcium regulation can stimulate PTH production. This is a hormonal and mineral complication, not a symptom that can be diagnosed from a feeling or appearance. A mildly elevated result does not mean the parathyroid glands are overactive for the same reason as in primary hyperparathyroidism. Many patients first learn about SHPT from routine blood tests and need help understanding how the values fit together.

Why PTH rises when kidney function declines

Healthy kidneys remove phosphate in urine and help convert vitamin D to its active form, calcitriol. As kidney function declines, the body may retain phosphate, produce less active vitamin D and absorb less calcium from food. PTH may increase to compensate for these changes. The hormonal response is influenced by fibroblast growth factor 23 (FGF23), dietary factors and the stage of kidney disease. These changes do not progress at the same speed in every person. PTH can start rising while blood phosphate remains in the laboratory reference range.

Persistently high PTH may contribute to increased bone turnover over time. However, CKD-MBD is the wider condition involving phosphate, calcium, PTH, bone health and possible calcification. SHPT is one part of this process. A high PTH result does not by itself establish renal osteodystrophy or predict an individual patient's risk of fracture.

What patients may notice

Early SHPT related to CKD often causes no distinctive symptoms. When mineral and bone problems have developed over time, some people report bone or joint pain, reduced mobility or fractures after relatively minor trauma. Others notice muscle cramps or persistent itching, although neither symptom is specific to raised PTH and both have many other explanations. Weakness or fatigue can also reflect anemia, medication effects or general kidney disease rather than SHPT itself.

The timing of symptoms matters. A gradual change in walking or persistent aching deserves a nonurgent review, whereas sudden severe bone pain after a fall or inability to bear weight requires prompt assessment for a possible fracture. New numbness, severe muscle spasms, seizures or concerning heart symptoms may reflect serious electrolyte or calcium abnormalities and should not be managed through a routine online inquiry.

How clinicians interpret PTH and related tests

A nephrologist usually reviews serial PTH results alongside calcium, phosphate, alkaline phosphatase and, when indicated, 25-hydroxyvitamin D. Kidney function can be assessed with serum creatinine and eGFR testing. Test interpretation depends on the degree of CKD and the laboratory method. A single elevated PTH value, especially if other values are changing, is less informative than its direction over time. In nondialysis CKD, an exact ideal PTH target has not been established.

Doctors also consider vitamin D deficiency, low calcium, high phosphate intake, medications and other causes of abnormal PTH. For patients with fractures or elevated skeletal risk, bone density testing or targeted imaging may be appropriate. Bone biopsy is rarely needed but can have a role in selected complex cases; it is not a standard diagnostic test for everyone with raised PTH. Primary and tertiary hyperparathyroidism may require different interpretation and specialist care.

When medical care is urgent

A routine rise in PTH is not usually an emergency. Urgent medical attention is appropriate for a suspected fracture, sudden inability to walk after injury or severe symptoms that suggest a serious calcium or electrolyte disturbance. Severe confusion, seizures, fainting, chest pain or abnormal heart rhythm require immediate assessment, whatever the most recent PTH result showed. Symptoms cannot reliably identify whether calcium, phosphate or potassium is responsible.

If a laboratory advises an immediate clinical review because of a critical calcium result, follow that advice rather than waiting for a scheduled consultation. Do not take extra calcium, vitamin D preparations or medications intended to lower PTH without review of the complete mineral profile.

Treatment depends on the trend and kidney disease stage

Treatment is chosen to address contributing factors and reduce complications, not simply to make one PTH value normal. In people with CKD who are not receiving dialysis, clinicians assess persistently rising PTH for modifiable factors such as vitamin D deficiency, hypocalcemia, hyperphosphatemia and dietary phosphate. The KDIGO CKD-MBD guideline does not recommend routine use of calcitriol or vitamin D analogs for all adults with nondialysis CKD; selected severe, progressive cases may require a different approach.

For patients on dialysis, treatment may include appropriate phosphate management, vitamin D receptor agents or calcimimetics under specialist supervision. Such medicines can affect calcium and phosphate and require monitoring. A small subgroup with severe SHPT that is not controlled with medical treatment may be considered for parathyroid surgery. A high PTH value alone is not a reason to start dialysis or perform surgery. Treatment decisions follow symptoms, repeated tests, CKD stage, fracture history and individual risks.

Choosing the next step with ZagrebMed

For someone with established CKD and a gradually rising PTH result, chronic kidney disease monitoring can bring the mineral findings into the longer-term treatment plan. A nephrology consultation is useful when PTH, calcium and phosphate values need specialist interpretation or treatment review. Patients with unexplained bone pain may also need examination for non-kidney causes; not every skeletal symptom can be attributed to SHPT.

Dr. Igor Žabić, a specialist in internal medicine and nephrology, practices at Sinteza Polyclinic in Zagreb. ZagrebMed can help direct a nonurgent inquiry within its network, but laboratory testing, medication availability and appointment suitability must be confirmed individually. His documented hospital experience in nephrology does not imply that all SHPT treatments are provided by Sinteza.

For the broader condition involving bones, mineral balance and vascular health, read about CKD mineral and bone disorder (CKD-MBD). If blood phosphate is persistently elevated, the separate page on hyperphosphatemia explains why phosphate sources, repeat testing and treatment selection matter. Elevated PTH and high phosphate can occur together, but they are not identical diagnoses.

Preparing your medical information

Before sending an inquiry, collect the dates and actual values for PTH, calcium, phosphate, alkaline phosphatase, vitamin D and creatinine/eGFR if available. Note the CKD stage, any dialysis prescription, previous fractures or bone density tests, existing calcium or vitamin D products, phosphate binders and other medication. Explain whether there is bone pain, itching, weakness or a change in walking, and when it started. Reports from another country can still help if the original units and reference ranges are visible.

Do not delay urgent care to gather paperwork. When the situation is stable, sharing both the earliest and most recent results often helps the clinician distinguish a persistent trend from one isolated abnormal measurement. These pages provide education and a route to an inquiry, not a diagnosis or individual treatment plan.

Clinical sources

  • KDIGO 2017 Clinical Practice Guideline Update for CKD-Mineral and Bone Disorder (CKD-MBD)
  • NIDDK: Mineral & Bone Disorder in Chronic Kidney Disease
  • National Kidney Foundation: Mineral and Bone Disorder (CKD-MBD)
  • KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD